Precision Nutrition in Gastric Cancer: Current Advances and Future Directions

Why It Matters

Tailoring nutrition to each patient’s metabolic phenotype can improve treatment tolerance, reduce complications, and ultimately enhance survival in gastric cancer—a disease where nutrition‑related morbidity drives poor outcomes.

Key Takeaways

• GLIM criteria combine intake, inflammation, and muscle loss for diagnosis
• CT‑based muscle index reveals hidden sarcopenia despite normal BMI
• Immunonutrition and microbiota modulation are emerging adjuncts to standard support
• AI tools can automate body‑composition analysis for rapid clinical use
• Prospective multicenter trials needed to prove precision nutrition benefits

Pulse Analysis

Gastric cancer patients frequently confront malnutrition and sarcopenia, conditions that traditional weight‑based metrics often miss. Recent advances in surgical techniques and systemic therapies have extended survival, yet nutritional deterioration remains a key barrier to optimal outcomes. Precision nutrition reframes care by integrating standardized risk screening, GLIM‑based malnutrition diagnosis, and quantitative imaging of muscle mass, allowing clinicians to identify high‑risk phenotypes early and intervene before severe weight loss occurs.

Beyond basic caloric and protein provision, the field is embracing novel modalities that target the underlying biology of cancer‑associated wasting. Immunonutrition—formulations enriched with omega‑3 fatty acids, arginine, and nucleotides—aims to modulate inflammatory pathways, while microbiota‑directed therapies seek to restore gut barrier function and nutrient absorption after gastrectomy. Concurrently, artificial‑intelligence algorithms can rapidly analyze routine CT scans to quantify skeletal muscle area and density, delivering actionable data without additional imaging burden. These technologies together create a more nuanced, phenotype‑driven approach that aligns nutritional support with each patient’s inflammatory and metabolic status.

The promise of precision nutrition hinges on robust clinical evidence. Current guidelines endorse standardized screening and GLIM criteria, but the impact of AI‑assisted assessments, multi‑omics integration, and targeted immunonutrition remains largely hypothesis‑driven. Large‑scale, multicenter trials are essential to determine whether these individualized strategies translate into reduced postoperative complications, improved chemotherapy tolerance, and longer survival. As the oncology community seeks to personalize therapy at the molecular level, extending that precision to nutrition could close a critical gap in comprehensive gastric‑cancer care.